Cantargia Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer

LUND, SE / ACCESSWIRE / August 27, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported currently expected timelines for nadunolimab clinical trials. The US FDA has granted MD Andersson Cancer Center the IND …
Jetzt den vollständigen Artikel lesen